Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Pleyer, L; Burgstaller, S; Stauder, R; Girschikofsky, M; Sill, H; Schlick, K; Thaler, J; Halter, B; Machherndl-Spandl, S; Zebisch, A; Pichler, A; Pfeilstöcker, M; Autzinger, EM; Lang, A; Geissler, K; Voskova, D; Geissler, D; Sperr, WR; Hojas, S; Rogulj, IM; Andel, J; Greil, R.
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
J Hematol Oncol. 2016; 9(6):39-39 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Autor/innen der Med Uni Graz:
Sill Heinz
Zebisch Armin

Dimensions Citations:

Plum Analytics:
Number of Figures: 2
| |
The MDS-IWG and NCCN currently endorse both FAB and WHO classifications of MDS and AML, thus allowing patients with 20-30 % bone marrow blasts (AML20-30, formerly MDS-RAEB-t) to be categorised and treated as either MDS or AML. In addition, an artificial distinction between AML20-30 and AML30+ was made by regulatory agencies by initially restricting approval of azacitidine to AML20-30. Thus, uncertainty prevails regarding the diagnosis, prognosis and optimal treatment timing and strategy for patients with AML20-30. Here, we aim to provide clarification for patients treated with azacitidine front-line. The Austrian Azacitidine Registry is a multicentre database ( NCT01595295). For this analysis, we selected 339 patients treated with azacitidine front-line. According to the WHO classification 53, 96 and 190 patients had MDS-RAEB-I, MDS-RAEB-II and AML (AML20-30: n = 79; AML30+: n = 111), respectively. According to the FAB classification, 131, 101 and 111 patients had MDS-RAEB, MDS-RAEB-t and AML, respectively. The median ages of patients with MDS and AML were 72 (range 37-87) and 77 (range 23-93) years, respectively. Overall, 80 % of classifiable patients (≤30 % bone marrow blasts) had intermediate-2 or high-risk IPSS scores. Most other baseline, treatment and response characteristics were similar between patients diagnosed with MDS or AML. WHO-classified patients with AML20-30 had significantly worse OS than patients with MDS-RAEB-II (13.1 vs 18.9 months; p = 0.010), but similar OS to patients with AML30+ (10.9 vs 13.1 months; p = 0.238). AML patients that showed MDS-related features did not have worse outcomes compared with patients who did not (13.2 vs 8.9 months; p = 0.104). FAB-classified patients with MDS-RAEB-t had similar survival to patients with AML30+ (12.8 vs 10.9 months; p = 0.376), but significantly worse OS than patients with MDS-RAEB (10.9 vs 24.4 months; p < 0.001). Our data demonstrate the validity of the WHO classification of MDS and AML, and its superiority over the former FAB classification, for patients treated with azacitidine front-line. Neither bone marrow blast count nor presence of MDS-related features had an adverse prognostic impact on survival. Patients with AML20-30 should therefore be regarded as having 'true AML' and in our opinion treatment should be initiated without delay.
Find related publications in this database (using NLM MeSH Indexing)
Acute Disease -
Adult -
Aged -
Aged, 80 and over -
Antimetabolites, Antineoplastic - therapeutic use
Austria -
Azacitidine - therapeutic use
Female -
France -
Humans -
Kaplan-Meier Estimate -
Leukemia, Myeloid - classification
Leukemia, Myeloid - diagnosis
Leukemia, Myeloid - drug therapy
Male -
Middle Aged -
Myelodysplastic Syndromes - classification
Myelodysplastic Syndromes - diagnosis
Myelodysplastic Syndromes - drug therapy
Outcome Assessment (Health Care) - methods
Outcome Assessment (Health Care) - statistics & numerical data
Prognosis -
Proportional Hazards Models -
Registries - statistics & numerical data
United Kingdom -
United States -
World Health Organization -

Find related publications in this database (Keywords)
Bone marrow blast count
Austrian Azacitidine Registry
© Meduni Graz Impressum